Innovative platform to screen CAR-T/TCR cancer immunotherapy drugs for off-target binding

点击翻译按钮获取中文摘要

Orbit Discovery Ltd was established in November 2015 as a spin-out from Oxford University. The founding IP relates to a peptide display platform and its use for the identification of novel peptides and for the identification of T-cell epitopes in high throughput screens. We provide services identifying and characterising advanced therapeutics for a range of chronic diseases.**Target Markets**Companies making modified TCRs as drug products for Cancer Immunotherapy have a current pressing need to identify off-target binding of their products to ensure safety; there have been several reported patient deaths in clinical trials due to cardiac or gastric inflammation as a direct result of treatment with modified TCRs.**Project Description**This project aims to investigate and validate a broad screening solution that would enable these companies to more comprehensively and reliably screen their products earlier in development. This would reduce the risk of medical side-effects or fatalities during clinical trials and would speed up the development and deployment of more effective cancer treatments.